Abstract

FC is most commonly used for routine, ongoing analgesia and sedation in newborns exposed to repeated pain and prolonged stress in the NICU. The hypothesis that FC exert effects on cerebrovascular prostaglandins was determined in 14 newborn pigs (1-3 days old), treated with either: a loading dose of FC (30 μg/kg i.v.) over 15 minutes, followed by a continuous infusion of FC (10 μg/kg/hr) for 6 hours (n=6); or 5% dextrose at 6 mg/kg/minute (placebo group, n=8). CSF from the cisterna magna was collected at 0 (pre-dose) and 6 hrs, and blood from the sagittal sinus vein was collected at 0 (pre-dose), 0.5, 2, 4 & 6 hrs during infusion for measurements of PGE2, 6-keto PGF1α and TXB2, by enzyme immunoassay. Our data show that in the FC group, CSF levels of PGE2 fell by 75% (p<0.001), and CSF levels of 6-ketoPGF1α and TXB2 increased by 150% and 80%, respectively, at 6 hrs of infusion. In addition, sagittal sinus plasma 6-keto PGF1α and TXB2 increased substantially at 0.5 hr and 2 hrs, with negligible effect on PGE2 levels. Values are mean±SD(pg/ml). *p<0.01, **p<0.001. We speculate that such marked changes in the levels of cerebrovascular prostanoids may contribute to adverse neurophysiologic effects, in newborns treated with FC.Table

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.